HE 3286

Drug Profile

HE 3286

Alternative Names: HE3286; Triolex

Latest Information Update: 22 Jul 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hollis-Eden Pharmaceuticals
  • Developer Harbor Therapeutics; The Michael J. Fox Foundation for Parkinson's Research
  • Class Anti-inflammatories; Antiepileptic drugs; Antihyperglycaemics; Hormones; Obesity therapies; Small molecules
  • Mechanism of Action Mitogen-activated protein kinase modulators; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cystic fibrosis

Highest Development Phases

  • Suspended Cystic fibrosis; Epilepsy; Parkinson's disease; Rheumatoid arthritis; Type 2 diabetes mellitus; Ulcerative colitis; Uveitis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 20 Jan 2012 Preclinical trials in Uveitis in USA (unspecified route)
  • 01 Mar 2011 HE 3286 is still in phase I/II development for Rheumatoid arthritis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top